New Delhi, July 9 -- Novo Nordisk India on Thursday launched Awiqli (insulin icodec) in the country, making India one of the markets to offer the world's first once-weekly basal insulin for adults living with Type 1 or Type 2 diabetes.

The new therapy reduces the number of insulin injections from one every day to one per week, cutting the annual requirement from 365 injections to just 52, reported ANI. According to the company, Awiqli represents a major shift in diabetes care, aiming to transform how insulin therapy fits into patients' daily lives rather than offering only a minor improvement over existing treatments.

Results from the global ONWARDS-1 clinical programme showed that Awiqli delivered greater reductions in HbA1c levels and...